奥比努图祖马布在活性系统性红斑狼的疗效和安全性
Richard A Furie1,2, Maria Dall'Era3, Edward M Vital4,5
1Northwell, New Hyde Park, NY.
The New England journal of medicine
|March 6, 2026
概括
与安慰剂相比,在患有活性系统性红斑狼 (SLE) 的成年人中,欧比努祖马布显著改善了治疗反应. 这种糖基工程抗体在第三阶段试验中,在初级和二级终点上表现出卓越的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥比努图祖马布是一种被批准用于狼性炎的抗CD20单克隆抗体.
- 它在活跃的全身性红斑狼 (SLE) 中的有效性需要进一步研究.
研究的目的:
- 评估奥比努图祖马布在患有活性SLE的成年人中的疗效和安全性.
- 在第三阶段临床试验中比较obinutuzumab与安慰剂.
主要方法:
- 一个多中心,双盲,安慰剂控制的第三阶段试验.
- 患有活性SLE的成年人接受了标准治疗加上奥比努图祖马布或安慰剂.
- 主要终点是SLE响应指数4 (SRI-4) 响应在52周.
主要成果:
- 奥比努图祖马布组的SRI-4反应率显著高 (76.7%) 与安慰剂相比 (53.5%) (P<0.001).
- 在所有关键次要终点中,奥比努图祖马布表现出优越性,包括基于BILAG的反应和降低葡萄糖皮质激素剂量.
- 不良事件发生率在各组之间是可比的,严重不良事件报告率为15.9% (奥宾图祖马布) 和11.9% (安慰剂).
结论:
- 在成年人治疗活跃SLE时,奥比努祖马布的效果优于安慰剂.
- 该研究支持obinutuzumab作为活跃SLE患者的有效治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
670
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
670
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
Bioequivalence studies: Biowaivers
353
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
353


